Skip to main content
Caplight Logo









FimmCyte

FimmCyte

Private
BaselHealthcare & Life Scienceshttps://fimmcyte.com/

Last Round

Convertible Debt

Feb 29, 2024

Total Funding Raised

$2.69M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

FimmCyte is a biotechnology company developing targeted immunotherapies for chronic fibro-inflammatory diseases with an initial focus on endometriosis.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

endometriosis treatmentdisease-modifying therapytargeted immunotherapyfirst-in-class drugnon-hormonal therapyantibody platformfibro-inflammatory diseasepreclinical biotechpharma licensingwomen's healthantibody therapyuniversity spin-off

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

FimmCyte Comparables

Compare FimmCyte with similar companies based on industry and business-model similarity.

FimmCyte comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Oriva Therapeutics
86%
EndoCyclic Therapeutics
84%
Sur180 Therapeutics
83%

FimmCyte Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Convertible DebtFeb 29, 2024
Convertible DebtSep 5, 2023
GrantJul 13, 2022

Key People

Founding team and executive leadership

Mohaned Shilaih

CEO

Executive Team

FimmCyte Investors

Notable investors and investment history

FimmCyte investors
InvestorRounds
Venture KickGrant
BioInnovation InstituteConvertible Debt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 13, 2026

    Open roles increased from 0 to 2, representing 29% of headcount.

  • Mar 25, 2025

    Monthly visitors grew 254% MoM, reaching 1.4K.

FimmCyte Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

FimmCyte Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about FimmCyte's valuation, stock price, and market status.

Firmographic Details

HeadquartersBasel
Employee Range7
Year Founded2022
Last FundingFeb 29, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?